WuXi Biologics
Offering End-to-End Solutions
Proprietary bispecific platform: WuXiBody® (Click here to WuXiBody® page)
Key Features of theWuXiBody® Platform:
Common light chain bispecific antibody through OmniFlic®
Bispecific antibody generation using generic formats
WuXi Biologics greatly simplifies ADC and other bioconjugate drug development by providing all stages of preclinical activities, holistic and integrated CMC development process, and the entire supply chain in one centralized region.(Click here)
WuXi Biologics offers biologics generation, including but not limited to: recombinant proteins, fusion proteins, cytokines, immunocytokines, peptides, nanobody, antibody fragments, and TCR based antibodies amongst others.